Consistently, immunohistochemical analysis confirmed that M2-like marker ARG1 and total TAM marker IBA1 were downregulated, while the CD8+ T cells marker CD8A increased in glioma allografts co-implanted with GL261-sLRIG3 and TAMs with exogenous full-length NETO2, compared with the blank or His-NETO2-Del1 group (Fig. 7g and Supplementary Fig. 5e, f). The gene discussed is ARG1; the disease is central nervous system cancer.